

Advancing the Science of Lung Cancer Treatment With Immuno-Oncology

Wednesday, 15 April 2015

18:30–19:30

Room A
Palexpo
Geneva, Switzerland

Chair's invitation


Dear colleagues,

On behalf of Bristol-Myers Squibb, it is my pleasure to invite you to a satellite symposium entitled 'Advancing the Science of Lung Cancer Treatment With Immuno-Oncology', as part of the 2015 European Lung Cancer Conference in Geneva, Switzerland.

In this symposium, we will discuss the role of the immune system in oncology, highlighting the immunogenic nature of lung cancer and the rationale for the immuno-oncology approach in this setting. The data emerging from the ongoing development of novel agents that modulate immune regulatory checkpoints in patients with lung cancer are very promising. Clinical data from several exploratory agents suggest the potential for achieving prolonged clinical benefit and provide new hope for these individuals.

Other topics will include efficacy and safety profiles from the latest clinical trial data for immune checkpoint inhibitors in lung cancer when used alone or in combination across a range of treatment settings. The role of biomarkers in the immuno-oncology setting will be discussed, including the complexity of identifying potential biomarkers. Finally, because immuno-oncology agents act via the immune system and are not tumour type specific, we will discuss the potentially broad clinical application of these agents.

We anticipate that the high levels of interaction and analysis provided by the symposium will inform and benefit your clinical practice, and look forward to welcoming you in Geneva.



Martin Reck

Germany

Programme

- | | |
|--------------|---|
| 18:30 | Welcome and introduction
<i>Martin Reck, Germany</i> |
| 18:35 | Exploring the potential for Immuno-Oncology in lung cancer
<i>Martin Reck</i> |
| 18:45 | Latest clinical evidence for targeting immune checkpoints in lung cancer
<i>Solange Peters, Switzerland</i> |
| 19:05 | Future considerations in the evolving lung cancer treatment landscape
<i>Keith Kerr, United Kingdom</i> |
| 19:25 | Concluding remarks
<i>Martin Reck</i> |
| 19:30 | Close |

Meal will be provided